|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, [<sup>89</sup>Zr]A2cDb immuno-PET showed antigen-specific targeting of PSCA-expressing tumors and minimal nonspecific uptake in PSCA-negative controls.
|
31209779 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, in mouse xenograft model, HPL-exposed CAR T cells outperformed their ABS or FBS counterparts against both subcutaneous tumor (P28z T cells against Capan-1<sup>PSCA</sup>) and systemic tumor (1928z T cells against NALM6).
|
31779709 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using pancreatic cancer as a model, we demonstrate how T cells engineered with receptors that recognize prostate stem cell antigen, TGFβ, and IL4, and whose endodomains recapitulate physiologic T-cell signaling by providing signals for activation, costimulation, and cytokine support, produce potent antitumor effects selectively at the tumor site.
|
29880586 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PSCA expression was associated with favorable pathological and clinical tumor features: Early pathological tumor stage (p < 0.0001), low Gleason grade (p < 0.0001), absence of lymph node metastasis (p < 0.0001), low pre-operative PSA level (p = 0.0118), negative surgical margin (p < 0.0001) and reduced PSA recurrence (p < 0.0001).
|
29855276 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, the scFv(AM1)-P-BAP showed highly PSCA-specific tumor retention with a PSCA<sup>+</sup> tumor/PSCA<sup>-</sup> tumor accumulation ratio of ten.
|
29491468 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When intravenously administered, PSCA-CAR T cells also showed tumor tropism, with a 9-fold greater tumor-to-muscle ratio than for CAR-negative T cells.
|
29728514 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrated that PSCA-targeting CAR T cells could efficiently suppress NSCLC tumor growth in PDX mice and synergistically eliminate PSCA<sup>+</sup>MUC1<sup>+</sup> tumors when combined with MUC1-targeting CAR T cells.
|
28405515 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSCA promoted PCa cell cycle progression and tumor growth via increased c-Myc expression.
|
28971496 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cases in the highest quartile (the smallest downregulation of tumor PSCA) had shortest survival than cases with the most downregulated PSCA (median survival of 0.47 years in the highest quartile versus 3.73 years in the lowest quartile; hazard ratio = 9.70; 95% CI = 2.46-38.4; P = 0.0012).
|
29028942 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, consistent with tumor regression, prostate stem cell antigen was considerably reduced in TLO and tumor areas from evanescent carcinoma patients.
|
28567040 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings support the benefit of combining the 4/7 ICR with CAR-PSCA to treat pancreatic cancer, a PSCA-expressing tumor characterized by a dense immunosuppressive environment rich in IL-4.
|
28129119 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, LNCaP-PSCA showed significantly enhanced primary tumor growth and metastasis formation of xenografts compared to LNCaP-vehicle and LNCaP cells (P < 0.001 for all).
|
26477693 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In previous work, we found that prostate stem cell antigen (PSCA) gene, encoding a glycosylphosphatidylinositol-anchored protein, is a presumable tumor suppressor in gastric cancer and gallbladder cancer (GBC).
|
25964537 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, RT-PCR PSCA positivity is significantly associated with the Gleason score, LV tumor emboli and whether or not the tumor was organ confined.
|
25698533 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
|
24694017 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the PSCA-CAR-engineered T cells efficiently kill PSCA-expressing tumor cells in vitro and systemic treatment with PSCA-CAR-engineered T cells significantly delays subcutaneous tumor growth and prolongs survival of mice.
|
24438073 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, our data indicate that rs2294008 of PSCA is involved in GC susceptibility and confer its effect primarily in noncardia tumors (OR = 1.30, 95% CI 1.12-1.53, P < 10(-4)).
|
24146278 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The study suggests that anti-PSCA immunotherapy might be beneficial for bladder cancer patients with high tumor PSCA expression, which is statistically significantly associated with the presence of CT and TT genotypes of a common genetic variant, rs2294008.
|
23266392 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.
|
23701419 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSCA is a tissue specific tumor suppressor or oncogene which has been found to be associated with several human tumors including gallbladder cancer.
|
23988503 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These lines of in vivo and in vitro evidence suggest that PSCA is acting as a tumor suppressor in GBC development.
|
21936014 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study is to develop an adoptive T cell transfer approach to target tumours expressing prostate stem cell antigen (PSCA), a tumour-associated antigen that is frequently expressed by pancreatic cancer cells.
|
21843265 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PSCA expression levels differ within heterogeneous tumor bulks and between human pancreatic cell lines, and we could show specific infection of pancreatic adenocarcinoma cell lines with both high- and low-level PSCA expression.
|
21701532 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The in vivo tumor growth study showed that immunization of mice with Ad5-PSA/PSCA vaccine induced strong antitumor immunity when challenged with mouse prostate tumor cell lines (RM11) expressing human PSA (RM11/PSA).
|
21668311 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shRNA against PSCA as revealed by GFP expression.
|
20374648 |
2010 |